AR035074A1 - Compuestos agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis, su uso en la fabricacion de medicamentos y composiciones farmaceuticas - Google Patents
Compuestos agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis, su uso en la fabricacion de medicamentos y composiciones farmaceuticasInfo
- Publication number
- AR035074A1 AR035074A1 ARP010105489A ARP010105489A AR035074A1 AR 035074 A1 AR035074 A1 AR 035074A1 AR P010105489 A ARP010105489 A AR P010105489A AR P010105489 A ARP010105489 A AR P010105489A AR 035074 A1 AR035074 A1 AR 035074A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally
- substituted
- mono
- alkanoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Agonistas de protaglandinas selectivos para el receptor EP4 de fórmula (1), un profármaco del mismo, una sal farmacéuticamente aceptable de dicho compuesto o de dicho profármaco, o un estereoisómero o una mezcla diastereomérica de dicho compuesto, profármaco o sal, donde: la línea discontinua es o no un enlace; X es -CH2- ó O; Z es -(CH2)3-, tienilo, tiazolilo o fenilo, con la condición de que cuando X es O, entonces Z es fenilo; Q es carboxilo, alcoxi C1-4-carbonilo o tetrazolilo; R2 es -Ar ó -Ar1-V-Ar2; V es un enlace, -O-, -OCH2- ó -CH2O-; Ar es un anillo de 5-8 miembros parcialmente saturado, totalmente saturado o totalmente insaturado que tiene opcionalmente de 1 a 4 heterátomos seleccionados independientemente entre O, S y N, o un anillo bicíclico que consta de 2 anillos de 5 ó 6 miembros condensados, independientemente parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de 1 a 4 heteroátomos seleccionados independientemente entre N, S y O, teniendo opcionalmente dicho anillo parcialmente saturado o totalmente saturado o anillo bicíclico 1 ó 2 grupos oxo sustituidos sobre carbono o 1 ó 2 grupos oxo sustituidos sobre azufre; y cada uno de Ar1 y Ar2 es independientemente un anillo de 5-8 miembros parcialmente saturado, totalmente saturado o totalmente insaturado que tiene opcionalmente de 1 a 4 heteroátomos seleccionados independientemente entre O, S y N, teniendo opcionalmente dicho anillo parcial o totalmente saturado 1 ó 2 grupos oxo sustituidos sobre carbono o 1 o 2 grupos oxo sustituidos sobre azufre; estando dicho resto Ar opcionalmente sustituido sobre carbono o nitrógeno, sobre un anillo si el resto es monocíclico o sobre uno o los dos anillos si es resto es bicíclico, con hasta 3 sustituyentes por anillo, seleccionados independientemente entre hidroxi, halo, carboxi, alcoxi C1-7, alcoxi C1-4-alquilo C1-4, alquilo C1-7, alquenilo C2-7, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-4, cicloalquil C3-7-alcanoílo C1-4, formilo, alcanoílo C1-8, alcanoil C1-6-alquilo C1-6, alcanoil C1-4-amino, alcoxi C1-4-carbonilamino, hidroxisulfonilo, aminocarbonilamino o aminocarbonilamino mono-N-, di-N,N-, di-N,N'-, o tri-N,N,N'-alquil C1-4 sustituido, sulfonamido, alquil C1-4-sulfonamido, amino, mono-N- o di-N,N-alquil C1-4-amino, carbamoílo, mono-N- o di-N,N-alquil C1-4-carbamoílo, ciano, tiol, alquil C1-6-tio, alquil C1-6-sulfinilo, alquil C1-6-sulfonolo y mono-N- o di-N,N-alquil C1-4-aminosulfinilo, estando dichos sustituyentes alquilo y alcoxi en la definición de Ar opcionalmente sustituidos sobre carbono con hasta 3 átomos de flúor; y estando dichos restos Ar1 y Ar2 independiente y opcionalmente sustituidos sobre carbono o nitrógeno con hasta 3 sustituyentes seleccionados cada uno de ellos independientemente entre hidroxi, halo, carboxi, alcoxi C1-7, alcoxi C1-4-alquilo C1-4, alquilo C1-7, alquenilo C2-7, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-4, cicloalquilo C3-7-alcanoílo C1-4, formilo, alcanoílo C1-8, alcanoil C1-6-alquilo C1-6, alcanoil C1-4-amino, alcoxi C1-4-carbonilamino, hidroxisulfonilo, aminocarbonilamino o aminocarbonil mono-N-, di-N,N'- o tri-N,N,N'-alquil C1-4 sustituido, sulfonamido, alquil C1-4-sulfonamido, amino, mono-N- o di-N,N-alquil C1-4-amino, carbamoílo, mono-N- o di-N,N-alquil C1-4-carbamoílo, ciano, tiol, alquil C1-6-tio, alquil C1-6-sulfinilo, alquil C1-4-sulfonilo y mono-N- o di-N,N-alquil C1-4-aminosulfinilo, estando dichos sustituyentes alquilo y alcoxi en la definición de Ar 1 y Ar2 opcionalmente sustituidos sobre carbono con hasta 3 átomos de flúor; con la condición de que (a) cuando X es (CH2)- y Z es -(CH2)3-, entonces R2 no es tienilo, fenilo o fenilo monosustituido con cloro, flúor, fenilo, metoxi, trifluorometilo o alquilo C1-4; y (b) cuando X es (CH2)-, Z es -(CH2)3- y Q es carboxilo o alcoxi C1-4-carbonilo, entonces R2 no es (i) cicloalquilo C5-7 o (ii) fenilo, tienilo o furilo, pudiendo estar cada uno de ellos opcionalmente monosustituido o disustituido con 1 ó 2 sustituyentes seleccionados independientemente, en el último caso, entre átomos de halógeno, grupos alquilo C1-3 que pueden estar sustituidos con uno o más átomos de halógeno, y grupos alcoxi C1-4. También se describen composiciones farmacéuticas que contienen estos compuestos. Estos compuestos son útiles para procedimientos de tratamiento de afecciones que presentan una baja masa ósea, particularmente osteoporosis, fragilidad, una fractura osteoporótica, un defecto óseo, pérdida de hueso idiopática infantil, pérdida de hueso alveolar, pérdida de hueso mandibular, fractura ósea, osteotomía, pérdida de hueso asociada con periodontitis o encarnamiento protésico en un mamífero. También se describe su uso en la preparación de medicamentos y composiciones que contienen dichos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25327500P | 2000-11-27 | 2000-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035074A1 true AR035074A1 (es) | 2004-04-14 |
Family
ID=22959588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010105489A AR035074A1 (es) | 2000-11-27 | 2001-11-26 | Compuestos agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis, su uso en la fabricacion de medicamentos y composiciones farmaceuticas |
Country Status (41)
Country | Link |
---|---|
US (3) | US6552067B2 (es) |
EP (1) | EP1339678B1 (es) |
JP (2) | JP3984164B2 (es) |
KR (1) | KR20030053063A (es) |
CN (1) | CN1476429A (es) |
AR (1) | AR035074A1 (es) |
AT (1) | ATE374182T1 (es) |
AU (1) | AU2002210848A1 (es) |
BG (1) | BG107697A (es) |
BR (1) | BR0115687A (es) |
CA (1) | CA2429850C (es) |
CY (1) | CY1106976T1 (es) |
CZ (1) | CZ20031257A3 (es) |
DE (1) | DE60130675T2 (es) |
DK (1) | DK1339678T3 (es) |
EA (1) | EA200300379A1 (es) |
EC (1) | ECSP034623A (es) |
EE (1) | EE200300246A (es) |
ES (1) | ES2291361T3 (es) |
GT (2) | GT200100238A (es) |
HN (1) | HN2001000266A (es) |
HU (1) | HUP0400807A2 (es) |
IL (1) | IL155368A0 (es) |
IS (1) | IS6775A (es) |
MA (1) | MA26961A1 (es) |
MX (1) | MXPA03004623A (es) |
NO (1) | NO20032360L (es) |
NZ (1) | NZ525164A (es) |
OA (1) | OA12533A (es) |
PA (1) | PA8533901A1 (es) |
PE (1) | PE20020637A1 (es) |
PL (1) | PL362030A1 (es) |
PT (1) | PT1339678E (es) |
SI (1) | SI1339678T1 (es) |
SK (1) | SK5562003A3 (es) |
SV (1) | SV2003000746A (es) |
TN (1) | TNSN01166A1 (es) |
TW (1) | TW200424170A (es) |
UY (1) | UY27038A1 (es) |
WO (1) | WO2002042268A2 (es) |
ZA (1) | ZA200302803B (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525164A (en) * | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
RU2288913C2 (ru) | 2001-07-16 | 2006-12-10 | Ф.Хоффманн-Ля Рош Аг | Аналоги простагландинов, способ их получения и фармацевтическая композиция, обладающая селективной агонистической активностью в отношении рецептора ep4 |
AU2002328338C1 (en) | 2001-07-16 | 2009-01-08 | Ono Pharmaceutical Co., Ltd | 2 pyrrolidone derivatives as prostanoid agonists |
MXPA04000757A (es) * | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
MXPA04008596A (es) | 2002-03-05 | 2004-12-06 | Ono Pharmaceutical Co | Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo. |
EP1487437B1 (en) * | 2002-03-18 | 2006-08-16 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of diseases |
MXPA04009036A (es) * | 2002-03-18 | 2005-01-25 | Pfizer Prod Inc | Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular. |
US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
WO2003103664A1 (en) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
WO2003103772A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma |
EP1556347A4 (en) * | 2002-06-10 | 2006-08-09 | Applied Research Systems | GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE |
GB0219143D0 (en) * | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
AU2003275838A1 (en) * | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2004043354A2 (en) | 2002-11-08 | 2004-05-27 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
CA2511255C (en) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
JP4582456B2 (ja) * | 2003-01-21 | 2010-11-17 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体およびその医薬用途 |
JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
WO2005012232A2 (en) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
US7576122B2 (en) | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
KR20060090801A (ko) | 2003-09-04 | 2006-08-16 | 머크 앤드 캄파니 인코포레이티드 | 고안압증 치료용 안용 조성물 |
JP2007504236A (ja) | 2003-09-04 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼用組成物 |
WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
BRPI0417621A (pt) * | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea |
US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
JP2008507521A (ja) | 2004-07-20 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科用組成物 |
JP4893999B2 (ja) * | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
US20080132543A1 (en) * | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
WO2006052630A1 (en) * | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
CA2586752A1 (en) * | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
KR100890490B1 (ko) * | 2005-01-27 | 2009-03-26 | 아사히 가세이 파마 가부시키가이샤 | 헤테로 6원환 화합물 및 그의 용도 |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
WO2006121708A1 (en) * | 2005-05-06 | 2006-11-16 | Allergan, Inc. | Substituted beta-lactams and their use in medicine |
US7772392B2 (en) | 2005-05-06 | 2010-08-10 | Allergan, Inc. | Therapeutic substituted β-lactams |
US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
KR100598678B1 (ko) * | 2006-02-15 | 2006-07-19 | (주)아이앤씨 | 수직형 대형 폐기물 파쇄기 |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
BRPI0721067A2 (pt) * | 2006-12-18 | 2014-02-25 | Allergan Inc | Métodos e composições para tratar distúrbios gastrointestinais. |
KR20100016299A (ko) | 2007-05-08 | 2010-02-12 | 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 | Ep4 아고니스트를 함유하여 이루어지는 세포 상해성 t 세포의 활성화제 |
WO2008144623A1 (en) * | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
US7705001B2 (en) * | 2008-03-18 | 2010-04-27 | Allergan, Inc | Therapeutic substituted gamma lactams |
EP2320906B1 (en) * | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
US20120190637A1 (en) | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
ES2593229T3 (es) * | 2010-03-08 | 2016-12-07 | Kaken Pharmaceutical Co., Ltd. | Nuevo agonista de EP4 |
CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
EP2397141A1 (en) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013105997A2 (en) | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814526B1 (en) | 2012-02-16 | 2016-11-02 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814527A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123270A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
KR102151578B1 (ko) * | 2012-07-19 | 2020-09-03 | 카이맨 케미칼 컴파니 인코포레이티드 | Ep4-매개의 골 관련 질병 및 질환을 위한 디플루오로락탐 조성물 |
JP6400479B2 (ja) | 2012-10-29 | 2018-10-03 | 株式会社カルディオ | 肺疾患特異的治療剤 |
JP6368351B2 (ja) | 2013-03-15 | 2018-08-01 | ケイマン ケミカル カンパニー, インコーポレーテッド | ジフルオロラクタムアナログを合成する方法 |
CA2906134A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
JP2016527006A (ja) | 2013-07-19 | 2016-09-08 | ケイマン ケミカル カンパニー, インコーポレーテッド | 骨成長を促進するための方法、システム、及び組成物 |
NZ717739A (en) | 2013-08-09 | 2023-12-22 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
BR112016028614A8 (pt) | 2014-06-06 | 2021-04-06 | Allergan Inc | novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso |
US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
EP3307747A4 (en) | 2015-06-12 | 2019-02-27 | Simon Fraser University | AMIDE-LINKED EP4-BISPHOSPHONATE AGONIST COMPOUNDS AND USES THEREOF |
CN107011377B (zh) * | 2017-05-03 | 2019-02-26 | 南通书创药业科技有限公司 | 一种β-羰基磷酸酯的制备方法 |
BR112020012405A2 (pt) | 2017-12-25 | 2020-11-24 | Asahi Kasei Pharma Corporation | composto cíclico de 6 membros contendo nitrogênio. |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1158163A (en) | 1966-06-15 | 1969-07-16 | Berk Ltd | Improvements in or relating to Polymer Compositions |
ZA72645B (en) * | 1971-03-05 | 1972-11-29 | Upjohn Co | Prostaglandin analogs |
DE2346706A1 (de) * | 1973-09-17 | 1975-04-03 | Hoechst Ag | Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung |
US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4177346A (en) * | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
TW288010B (es) | 1992-03-05 | 1996-10-11 | Pfizer | |
SE9302334D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
ZA944647B (en) | 1993-07-06 | 1995-01-06 | Astra Ab | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives |
US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
TW420669B (en) | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
WO2000021532A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
JP2002527400A (ja) * | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨形成刺激方法 |
TR200201643T2 (tr) * | 1999-12-22 | 2002-11-21 | Pfizer Products Inc. | Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler. |
DE60120007T2 (de) * | 2000-01-31 | 2006-11-16 | Pfizer Products Inc., Groton | Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
NZ525164A (en) * | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
2001
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 EP EP01978757A patent/EP1339678B1/en not_active Expired - Lifetime
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en active IP Right Grant
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
-
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
-
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035074A1 (es) | Compuestos agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis, su uso en la fabricacion de medicamentos y composiciones farmaceuticas | |
AP2001002357A0 (en) | EP4 receptor selective agonists in the treatment of osteoporosis. | |
ECSP105163A (es) | Composiciones farmaceuticas de agonista parcial de 5ht4 | |
PE20040418A1 (es) | Nuevas formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion | |
HUP0303271A2 (hu) | Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására | |
MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
NO20060329L (no) | Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse | |
AR030045A1 (es) | Composicion farmaceutica que contiene compuestos antibioticos de azalida , metodos para obtencion | |
AR034555A1 (es) | Compuestos de 1,4-dihidropiridina como antagonistas de bradicinina; composicion farmaceutica, compuesto intermediario, procedimiento para preparar dichos compuestos | |
BRPI0518781A2 (pt) | formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, e, uso de um composto | |
BRPI0417621A (pt) | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea | |
BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
BRPI0614197B8 (pt) | composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição | |
AR037687A1 (es) | Composiciones farmaceuticas a base de derivados de azetidina | |
PE20051049A1 (es) | Composiciones farmaceuticas que comprenden un antagonista de neuroquinina nk1 | |
BR9916845A (pt) | Compostos de (aminoiminometil ouaminometil)benzo-heteroarila substituìdos | |
CL2004000765A1 (es) | Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo. | |
HUP0401042A2 (hu) | Primer álmatlanság kezelésére alkalmas gyógyszerkészítmények | |
BRPI0519248A2 (pt) | formulaÇço oral de liberaÇço imediata de um composto ativo, e, mÉtodo para a preparaÇço de uma formulaÇço | |
CR6952A (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis | |
BR0013291A (pt) | Composiçao de vidro, e, dispositivo de liberação de fluoreto para o tratamento e/ou prevenção da cárie dentária | |
UY28618A1 (es) | Nuevos indoles sustituidos de piperidina o heteroderivados de los mismos | |
GT200000086A (es) | Polimorfos de un citrato de azobiciclo [2.2.2]oct-3-ilamina cristalino y sus composiciones farmaceuticas. | |
ECSP045163A (es) | Composiciones farmaceuticas de agonista parcial de 5ht4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |